We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Spring clean

22 April 2014 By Chris Hughes

The pharma giants are swapping assets worth up to $23 bln and merging others to focus on their respective strengths. Investors are cheering synergies, capital discipline and strategic focus. It’s a way to transform both businesses while avoiding the perils of a mega-merger.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)